Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform
Sightera Biosciences, a Belgiantechbio company using generative AI to develop novel small-molecule therapies,has raised €3 million in a pre-seed funding round led by Entourage, Anacura andQBIC.A…
Read the full articleYou might also wanna read
Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform
Sightera Biosciences, an Antwerp-based AI drug discovery startup and spin-off from the University of Antwerp (UA) and Antwerp University Hos
Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from ‘extreme’ patient biology first
Most AI drug discovery companies start by selecting a target and designing a molecule, then seeking biological validation.…
Verge Genomics Hiring for Engineering and Product Roles to Advance AI Drug Discovery
Verge is using AI to develop better drugs faster. We are one of the few AI drug discovery companies to advance from data to clinic – deliver
news.ycombinator.com·9mo agoPharma’s AI Boom Has Bet on the Wrong Bottleneck
Investors have poured billions into using artificial intelligence to discover new drugs, and 2026 is the first real test of whether AI-desig
Perceptic raises $12m seed round to build unified AI platform for drug development
Perceptic has raised a $12m (£9m) seed round led by Accel, Air Street Capital and Elder Gull to accelerate its build of a single AI system t
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engager
Comments
Sign in to join the conversation.
No comments yet. Be the first.